Cargando…
Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept
Tuberculosis is an infectious disease caused by the bacterial complex Mycobacterium tuberculosis. Despite the decline in the incidence and mortality of this disease over the years, the emergence of new strains of tuberculosis resistant to existing tuberculostatic drugs is currently one of the larges...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647364/ https://www.ncbi.nlm.nih.gov/pubmed/37958633 http://dx.doi.org/10.3390/ijms242115648 |
_version_ | 1785135089828495360 |
---|---|
author | Gonçalves, Joana Marques, Cláudia Nunes, Cláudia Sarraguça, Mafalda |
author_facet | Gonçalves, Joana Marques, Cláudia Nunes, Cláudia Sarraguça, Mafalda |
author_sort | Gonçalves, Joana |
collection | PubMed |
description | Tuberculosis is an infectious disease caused by the bacterial complex Mycobacterium tuberculosis. Despite the decline in the incidence and mortality of this disease over the years, the emergence of new strains of tuberculosis resistant to existing tuberculostatic drugs is currently one of the largest public health problems. The engineering and development of new drugs is a complex process; therefore, the modification and enhancement of the drugs already marked is a better and faster solution. Ethambutol (ETB) is an antimycobacterial drug used to treat tuberculosis; however, it is highly hygroscopic and is sparingly soluble in water. Therapeutic Deep Eutectic Solvents (THEDESs) are known to improve drug solubility, permeability, and hygroscopicity, among others. In this study, three THEDESs of ETB were synthesized with sucralose, glucose and glycerol and then encapsulated in nanostructured lipid carriers to improve their stability. This work is a proof of concept on the possibility of encapsulating the THEDESs, and results show that the encapsulation of ETB is possible, yielding formulations with a loading capacity superior to 8.5% and able to incorporate THEDESs and not just ETB. |
format | Online Article Text |
id | pubmed-10647364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106473642023-10-27 Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept Gonçalves, Joana Marques, Cláudia Nunes, Cláudia Sarraguça, Mafalda Int J Mol Sci Article Tuberculosis is an infectious disease caused by the bacterial complex Mycobacterium tuberculosis. Despite the decline in the incidence and mortality of this disease over the years, the emergence of new strains of tuberculosis resistant to existing tuberculostatic drugs is currently one of the largest public health problems. The engineering and development of new drugs is a complex process; therefore, the modification and enhancement of the drugs already marked is a better and faster solution. Ethambutol (ETB) is an antimycobacterial drug used to treat tuberculosis; however, it is highly hygroscopic and is sparingly soluble in water. Therapeutic Deep Eutectic Solvents (THEDESs) are known to improve drug solubility, permeability, and hygroscopicity, among others. In this study, three THEDESs of ETB were synthesized with sucralose, glucose and glycerol and then encapsulated in nanostructured lipid carriers to improve their stability. This work is a proof of concept on the possibility of encapsulating the THEDESs, and results show that the encapsulation of ETB is possible, yielding formulations with a loading capacity superior to 8.5% and able to incorporate THEDESs and not just ETB. MDPI 2023-10-27 /pmc/articles/PMC10647364/ /pubmed/37958633 http://dx.doi.org/10.3390/ijms242115648 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gonçalves, Joana Marques, Cláudia Nunes, Cláudia Sarraguça, Mafalda Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept |
title | Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept |
title_full | Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept |
title_fullStr | Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept |
title_full_unstemmed | Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept |
title_short | Therapeutic Liquid Eutectic Solvents in Lipid Nanoparticles as Drug Vehicles—A Proof of Concept |
title_sort | therapeutic liquid eutectic solvents in lipid nanoparticles as drug vehicles—a proof of concept |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647364/ https://www.ncbi.nlm.nih.gov/pubmed/37958633 http://dx.doi.org/10.3390/ijms242115648 |
work_keys_str_mv | AT goncalvesjoana therapeuticliquideutecticsolventsinlipidnanoparticlesasdrugvehiclesaproofofconcept AT marquesclaudia therapeuticliquideutecticsolventsinlipidnanoparticlesasdrugvehiclesaproofofconcept AT nunesclaudia therapeuticliquideutecticsolventsinlipidnanoparticlesasdrugvehiclesaproofofconcept AT sarragucamafalda therapeuticliquideutecticsolventsinlipidnanoparticlesasdrugvehiclesaproofofconcept |